A Study of the PedSCath Pediatric Sampling Catheter Versus Current Standard of Care.

NCT ID: NCT04763967

Last Updated: 2023-06-22

Basic Information

• Recruitment Status: TERMINATED
• Total Enrollment: 2 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2021-08-27
• Study Completion Date: 2023-02-02

Brief Summary

This is a retrospectively-controlled clinical trial that will examine the rate of positive UTI cases among pediatrics entered into the Emergency Department and whose urine is withdrawn using the PedSCath Pediatric Sampling Catheter. The rate of postive UTI will be compared against the control population, whose urine withdrawal would have been performed with Standard of Care devices.

Detailed Description

This will be a multi-center, retrospective-controlled, clinical trial.

Anonymized retrospective data from two clinical sites, NewYork-Presbyterian Queens and Weill Cornell Medical College, from 2016 and 2018 will be used to define the control subject population, who were assessed for urinary tract infection (UTI) based on a urine sample taken according to Standard of Care (SoC).

Subjects entering the emergency department (ED) generally require that a urine specimen is obtained and tested to determine whether there is an active infection in the bladder. Emergency department personnel will confirm the possibility of UTI based on symptoms and inform the parents/guardians of the potential for study participation using the PedSCath. The physician will assess the subject based on Inclusion and Exclusion criteria, including non-toilet training and an upper age limit of 3 years. If determined that the subject meets inclusion/exclusion criteria, the physician will inform the parents/guardians of the subject about the study and request informed consent if the parents/guardians wish their child to participate.

Following the granting of Informed Consent, subjects will be enrolled in the study within the treatment arm and a urine sample of 2-3 ml will be taken via the PedSCath. All study assessments, from enrollment through urine sample collection, will occur over a single visit to the ED. Per standard of care, any treatment following the diagnosis will be performed by hospital staff based on physician assessment. Up to 3 run-in subjects per PedSCath user will be treated with PedSCath to allow PedSCath users to become familiar with PedSCath mechanism.

Conditions

Urinary Tract Infections in Children

Study Design

• Observational Model Type: COHORT
• Study Time Perspective: OTHER

Study Groups

PedSCath

Subjects in this arm will be catheterized with the PedSCath Pediatric Urinary Cather.

PedSCath Pediatric Urinary Catheter

Intervention Type: DEVICE

PedSCath Pediatric Sampling Catheter is a pediatric sampling catheter. The product is supplied as a catheter and syringe. PedSCath Pediatric Sampling Catheter is manufactured by Medical Murray Inc. for Big Blue Biotech. The device consists of a blend of LDPE/Elvax/Crodamide.

Retrospective Control

Generated from 2016 and 2018 anonymized subject data from the clinical sites.

Standard of Care

Intervention Type: DEVICE

Current Standard of Care for pediatric patients

Interventions

PedSCath Pediatric Urinary Catheter

PedSCath Pediatric Sampling Catheter is a pediatric sampling catheter. The product is supplied as a catheter and syringe. PedSCath Pediatric Sampling Catheter is manufactured by Medical Murray Inc. for Big Blue Biotech. The device consists of a blend of LDPE/Elvax/Crodamide.

Intervention Type: DEVICE

Standard of Care

Current Standard of Care for pediatric patients

Intervention Type: DEVICE

Other Intervention Names

Wiygul Catheter

Eligibility Criteria

Inclusion Criteria

• Subject is 3 years of age or younger.
• Subject is non-toilet trained, as communicated by subject's parent/guardian.
• Subject is presenting to the emergency department with symptoms for UTI, as described by AAP guidelines (Newborns with UTI may present with jaundice, sepsis, failure to thrive, vomiting, or fever. In infants and young children, typical signs and symptoms include fever, strong-smelling urine, hematuria, abdominal or flank pain, and new-onset urinary incontinence) or as determined by PI.
• Subject's parent/guardian is able to provide informed consent.

Exclusion Criteria

• Any subject with known underlying abnormalities to the genitourinary tract (e.g. prenatal hydronephrosis).
• Any subject who has had prior genitourinary tract or abdominal surgery.
• Any subject who is toilet trained (i.e. able to provide a clean catch urine sample).
• Any subject with an active rash or skin lesion in the suprapubic area.
• Any subject with a known allergy to LDPE, Elvax, or Crodamide plastics.

• Maximum Eligible Age: 3 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Big Blue Biotech, Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Evan M Haynes, MA

Role: STUDY_CHAIR

Big Blue Biotech, Inc.

Locations

NewYork-Presbyterian Queens

New York, New York, United States

Countries

United States

Other Identifiers

BBBInc: 0619

Identifier Type: -

Identifier Source: org_study_id